Frederique Menzaghi
Overview
Explore the profile of Frederique Menzaghi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
901
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stander S, Fishbane S, Schaufler T, Ruessmann D, Morin I, Menzaghi F, et al.
Clin Kidney J
. 2024 Oct;
17(10):sfae274.
PMID: 39421431
Background: Pruritus is a common condition in chronic kidney disease (CKD), especially for patients receiving haemodialysis. CKD-associated pruritus (CKD-aP) can be distressing and have a negative impact on quality of...
2.
Spencer R, Noonan P, Marbury T, Menzaghi F
BMC Nephrol
. 2024 Oct;
25(1):351.
PMID: 39402448
Background: Difelikefalin is a selective kappa opioid receptor agonist that is approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis (HD). In this...
3.
Fishbane S, Block G, Evenepoel P, Budden J, Morin I, Menzaghi F, et al.
Kidney360
. 2024 Jul;
5(9):1270-1280.
PMID: 39037824
No abstract available.
4.
Fishbane S, Clegg D, Lerma E, Rastogi A, Budden J, Morin I, et al.
Am J Nephrol
. 2024 Jan;
55(3):329-333.
PMID: 38253036
Introduction: Black and African American (AA) people are over-represented in the kidney failure population; therefore, the safety and efficacy of difelikefalin in Black/AA patients was evaluated. Methods: This was a...
5.
Scherer J, Tu C, Pisoni R, Speyer E, Lopes A, Wen W, et al.
Kidney Med
. 2024 Jan;
6(1):100754.
PMID: 38225976
Rationale & Objective: Itching is a frequent symptom experienced by people with chronic kidney disease (CKD). We investigated the associations of CKD-associated pruritus (CKD-aP) with clinical outcomes. Study Design: This...
6.
Weiner D, Schaufler T, McCafferty K, Kalantar-Zadeh K, Germain M, Ruessmann D, et al.
Nephrol Dial Transplant
. 2023 Nov;
39(7):1125-1137.
PMID: 37968132
Background: Poor sleep quality is associated with higher mortality and lower quality of life in patients with chronic kidney disease-associated pruritus (CKD-aP). Difelikefalin reduces itch in patients with CKD-aP undergoing...
7.
Menzaghi F, Vernon M, Mattera M, Cirulli J, Wen W, Spencer R, et al.
Kidney Med
. 2023 Aug;
5(9):100696.
PMID: 37637864
Rationale & Objective: Despite its prevalence and distress to patients, chronic kidney disease-associated pruritus (CKD-aP) is poorly characterized, which may contribute to the condition's underdiagnosis and inadequate management. This study...
8.
Stark J, Noonan P, Spencer R, Bhaduri S, OConnor S, Menzaghi F
Clin Pharmacokinet
. 2023 Jun;
62(9):1231-1241.
PMID: 37369955
Background And Objective: Difelikefalin, a selective kappa-opioid receptor agonist, is the first approved treatment for moderate-to-severe pruritus in patients with end-stage renal disease (ESRD) on hemodialysis (HD) in the USA...
9.
Spencer R, Munera C, Shram M, Menzaghi F
Clin Transl Sci
. 2023 May;
16(9):1559-1568.
PMID: 37128642
Difelikefalin is a selective kappa opioid receptor agonist approved for treating moderate-to-severe pruritus in adults undergoing hemodialysis (HD). Difelikefalin is not a controlled substance under the Controlled Substances Act. This...
10.
Yosipovitch G, Awad A, Spencer R, Munera C, Menzaghi F
J Am Acad Dermatol
. 2023 Apr;
89(2):261-268.
PMID: 37059302
Introduction/background: Chronic pruritus is burdensome for patients with chronic kidney disease (CKD). Objective: We evaluated difelikefalin efficacy and safety in reducing itch in subjects with non-dialysis-dependent CKD and those undergoing...